Enveric Biosciences Inc. - news published 259 - readings 4.307

BACK
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Press Releases Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds By wpengine December 2, 2024 No Comments New patents provide additional composition of matter and methods of use claims for Enveric's EVM301 series neuroplastogenic molecules, and recently out-licensed tryptamine-derived prodrugs, including EB-002, a new chemical ...

Continue reading
02.12.2024
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB 003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination like Behavior

Press Releases Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior By wpengine November 25, 2024 No Comments Dose-proportional oral bioavailability without clinical signs, including those associated with hallucinogenic compounds, was demonstrated in ra ...

Continue reading
25.11.2024
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Press Releases Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results By wpengine November 14, 2024 No Comments Advanced pre-IND activities and research for lead candidate, EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders Announced the expansion of patent protection for a broad range of molecules in its EVM301 p ...

Continue reading
15.11.2024
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results Form 8 K

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results Advanced pre-IND activities and research for lead candidate, EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders Announced the expansion of patent protection for a broad range of molecules in its EVM301 portfolio, including five previously unannounced US patent ...

Continue reading
14.11.2024
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___ to ___ Commission File ...

Continue reading
14.11.2024
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Signs Out Licensing Agreement with MycoMedica Life Sciences for EB 002 Form 8 K

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 Agreement includes development and sales milestones payments potentially totaling up to $62 million as well as tiered single digit royalties on future sales CAMBRIDGE, Mass., November 12, 2024 - Enveric Biosciences, Inc . (NASDAQ: ENVB) ("Enveric" or the "Company"), a ...

Continue reading
12.11.2024
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Press Releases Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 By wpengine October 15, 2024 No Comments In vitro pharmacology studies confirmed EB-003's ability to target desired serotonergic receptors, supporting the potential of the neuroplastogenic therapeutic candidate to address difficult-to-treat mental health disorders withou ...

Continue reading
15.10.2024